
    
      We dichotomize patients according to the risk of CNS involvement. Then, we perform CNS
      evaluation in patients at risk of CNS involvement. We prospectively monitor whether CNS
      relapse or metastasis occurs in patients with diffuse large B-cell lymphoma
    
  